| abstract |
This specification describes (S) -2- (5-((3-ethoxypyridine-2-yl) oxy) pyridine-for treating diseases including non-alcoholic steatohepatitis (NASH) in mammals. 3-Il) -N- (tetratetra-3-yl) pyrimidin-5-carboxamide or a pharmaceutically acceptable salt thereof and 4- (4- (1-isopropyl-7-oxo-1,4,6,7) -Tetrahydrospiro [indazole-5,4'-piperidine] -1'-carbonyl) -6-methoxypyridin-2-yl) A combination of benzoic acid or a pharmaceutically acceptable salt thereof is described. FIG. 18 |